Team:Trieste/parts/4
From 2012.igem.org
(Difference between revisions)
Drikicmarija (Talk | contribs) |
Drikicmarija (Talk | contribs) |
||
Line 13: | Line 13: | ||
This construct is designed for the expression of an already descibed engeneered antinorovirus (NoV) monoclonal antibody (mAb 54.6) in fusion with LPP-OmpA. The antibody is expressed in a single chain fragment variable (scFv) format containing light (VL) and heavy (VH) variable domains separeted by a flexible peptide linker. It has already been reported that the scFv 54.6 binds a native recombinant NoV particles (VLPs) and inhibits VLP interaction with cells. LPP-OmpA functions as a leader sequence and an anchor to display the scFv ot the bacterial surface. | This construct is designed for the expression of an already descibed engeneered antinorovirus (NoV) monoclonal antibody (mAb 54.6) in fusion with LPP-OmpA. The antibody is expressed in a single chain fragment variable (scFv) format containing light (VL) and heavy (VH) variable domains separeted by a flexible peptide linker. It has already been reported that the scFv 54.6 binds a native recombinant NoV particles (VLPs) and inhibits VLP interaction with cells. LPP-OmpA functions as a leader sequence and an anchor to display the scFv ot the bacterial surface. | ||
<h2>Assembly</h2> | <h2>Assembly</h2> | ||
- | </br> | + | </br> |
+ | Obtained by synthesis. | ||
+ | </br> | ||
<h2>Results</h2> | <h2>Results</h2> | ||
</br> | </br> |
Revision as of 17:12, 25 September 2012